Dmitry Balyasny’s Inovio Pharmaceuticals INO Stock Holding History

Dmitry Balyasny’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-22,246	Closed	-$309K	–	2825
2024 Q1	$309K	Buy	+22,246	New	+$192K	﹤0.01%	2249
2023 Q4	–	Sell	-1,524	Closed	-$7.11K	–	2682
2023 Q3	$7.11K	Sell	1,524 -5,662	-79%	-$31.3K	﹤0.01%	2186
2023 Q2	$38.5K	Buy	+7,186	New	+$57.9K	﹤0.01%	2139
2023 Q1	–	Sell	-4,055	Closed	-$75.9K	–	2892
2022 Q4	$75.9K	Sell	4,055 -1,389	-26%	-$31.5K	﹤0.01%	2284
2022 Q3	$113K	Buy	5,444 +737	+16%	+$18.9K	﹤0.01%	2395
2022 Q2	$98K	Buy	+4,707	New	+$133K	﹤0.01%	2283
2020 Q2	–	Sell	-27,791	Closed	-$2.48M	–	1303
2020 Q1	$2.48M	Buy	+27,791	New	+$1.71M	0.03%	575
2016 Q1	–	Sell	-2,992	Closed	-$241K	–	1385
2015 Q4	$241K	Buy	+2,992	New	+$238K	﹤0.01%	1042

Other funds holding INO

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Dmitry Balyasny's INO Position: Q2 2024 in Review

Dmitry Balyasny sold out of Inovio Pharmaceuticals (INO) in Q2 2024, closing a stake of 22,246 shares — an estimated $309K sold.

Dmitry Balyasny first reported a position in INO in Q4 2015 and held it in 8 quarters. The position peaked at $2.48M in Q1 2020. 96 funds tracked by Wall St. Rank hold INO as of Q2 2024.

Dmitry Balyasny reported no remaining Inovio Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Dmitry Balyasny sold 22,246 Inovio Pharmaceuticals shares in Q2 2024, an estimated $309K.
Dmitry Balyasny first reported a position in Inovio Pharmaceuticals in Q4 2015 and held it in 8 quarters.
Dmitry Balyasny's Inovio Pharmaceuticals position peaked at $2.48M in Q1 2020.
96 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.